Here's something you don't see every day: health insurance stocks celebrating a government announcement. But that's exactly what happened Monday when the Centers for Medicare & Medicaid Services (CMS) dropped its final 2027 Medicare Advantage rates, and they were... actually pretty good.
Remember back in January when CMS proposed rates that would have amounted to basically a rounding error increase? The market certainly does - stocks like UnitedHealth Group Inc. (UNH), Humana Inc. (HUM), and CVS Health Corporation (CVS) took a hit on fears that Medicare Advantage, the private version of Medicare that's become a huge profit center for insurers, was about to get squeezed.
Well, turns out the government was listening. The final numbers came out Monday, and they're much better than what was on the table a few months ago.
The Numbers That Made Everyone Smile
CMS is projecting a 2.48% increase in payments to Medicare Advantage plans for 2027. That's not just a percentage point - it's over $13 billion in actual dollars flowing to insurers.
But here's where it gets interesting. When you account for what they call the "risk score trend" - basically how sick the Medicare population is expected to be, and how well insurers document those conditions - the effective increase jumps to 4.98%.
Compare that to the advance notice in January, which expected a net average year-over-year payment increase of just 0.09%. That's the difference between getting a cost-of-living adjustment and getting a real raise. The initial proposal would have meant about $700 million in additional payments. The final version? More than $13 billion.
No wonder the stocks are moving.
Who Benefits From This?
Pretty much every company with significant Medicare Advantage exposure. That includes:
Humana and UnitedHealth are the purest plays here - Medicare Advantage is core to their businesses. For CVS, it's part of their Aetna insurance arm. But they all stand to benefit from higher payments.
The Other Big Win: Stability
Here's something that might sound technical but actually matters a lot: CMS decided to keep using the 2024 Medicare Advantage risk adjustment model for 2027.
What does that mean in English? The government has a formula for figuring out how much to pay insurers based on how sick their members are. They were thinking about updating that formula with newer data, which could have changed payments in unpredictable ways.
Instead, they're sticking with the current formula. For insurers, this is huge. It means more predictability. They've already adjusted to how this model works, and they won't have to figure out a new one next year.
There are some technical tweaks - CMS is excluding diagnoses from audio-only doctor visits and certain types of medical records from the risk score calculation, with an exception for when patients switch between Medicare Advantage plans. But the big picture is: the rules aren't changing as much as they could have.
Why This Matters Beyond the Numbers
Analysts at William Blair pointed out that the main reason the final rates were better than the initial proposal was a smaller impact from risk model revisions. Where the advance notice suggested a 3.35% reduction from model changes, the final notice only has a 1.12% reduction.
Analyst Ryan Daniels called this "a positive sign for the MA space" because it shows CMS "was willing to listen to industry participants."
Think about that for a second. In the world of government-regulated industries, predictability is almost as valuable as profitability. When insurers can't predict what the rules will be next year, they get conservative. They might pull back from certain markets or be less aggressive about adding benefits.
This announcement suggests CMS wants to give the Medicare Advantage market some breathing room. They're saying, in effect: "We know you just adjusted to the 2024 model, so we'll let you keep using it while you figure things out."
That improves what analysts call "revenue visibility" - basically, insurers can see further into the future with more confidence. And when insurers are confident, they're more likely to invest in their plans, add benefits, and compete for members.
The Market's Verdict
Investors liked what they heard. Like, really liked it.
CVS Health rose 3.36% to $75.73. Humana gained 4.45% to $190.78. UnitedHealth Group climbed 7.52% to $302.51. Elevance Health advanced 3.07% to $311.91.
But look at some of the smaller players: Alignment Healthcare surged 14.46% to $21.37. Astrana Health rose 5.42% to $27.41. Oscar Health added 1.25% to $12.92.
Centene edged up 0.48% to $35.57, while Molina Healthcare was the odd one out, declining 2.50% to $139.78.
The takeaway? When the government gives an industry a pleasant surprise, the market notices. And in this case, it's not just about the dollars - it's about the message that Medicare Advantage, which now covers more than half of all Medicare beneficiaries, isn't about to get squeezed as hard as some feared.
For investors, that means the thesis for owning these stocks - that Medicare Advantage will continue to grow and be profitable - just got a little stronger. And for the companies themselves, it means they can plan for 2027 with a bit more certainty about what the rules will be.
Not bad for a Monday announcement from a government agency.
